Entheon Announces Completion of Amalgamation and Final Approval from the Canadian Securities Exchange

Original Source – Newsfile Corp.

Vancouver, British Columbia–(Newsfile Corp. – November 5, 2020) – Entheon Biomedical Corp. (CSE: MPV) (formerly, MPV Exploration Inc.) (“Entheon” or the “Company“) is pleased to announce that further to its news releases dated July 2, 2020, September 10, 2020 and October 28, 2020, the Company has completed the previously announced business combination with Entheon Holdings Corp. (formerly, Entheon Biomedical Corp.) and has received final approval to list the Resulting Issuer Shares (as defined below) on the Canadian Securities Exchange (“CSE“) pursuant to the amalgamation agreement (the “Amalgamation Agreement“) dated June 30, 2020, as amended, among the Company, Entheon Holdings Corp. and 1254912 B.C. Ltd.

Entheon will list 34,353,688 common shares (the “Resulting Issuer Shares“) on the CSE and the Resulting Issuer Shares are expected to begin trading on or about November 12, 2020 (the “Trading Resumption Date“) under the symbol “ENBI”.

Further Disclosure

Trading in the common shares of the Company was halted by the CSE on July 2, 2020 following the announcement of the Amalgamation Agreement and is expected to remain halted until the Trading Resumption Date.

Further, a total of 1,988,500 common share purchase warrants of the Company issued in connection with the Company’s Initial Public Offering in April 2018 (the “Warrants“) have been assigned a new CUSIP number and ISIN number, being 29383X111 and CA29383X1116, respectively, expected to be made eligible on or about November 10, 2020, with each Warrant now exercisable for one Resulting Issuer Share at a price of $0.90 per share until April 20, 2021.

For further information with respect to the Transaction and the business of Entheon, please refer to the listing statement of Entheon dated November 12, 2020 and posted under the Company’s issuer profile on SEDAR at www.sedar.com.

About Entheon Biomedical Corp.

Entheon is a biotechnology research and development company committed to developing and commercializing a portfolio of safe and effective Dimethyltryptamine based psychedelic therapeutic products (“DMT Products“) for the purposes of treating addiction and substance use disorders. Subject to obtaining all requisite regulatory approvals and permits, Entheon intends to generate revenue through the sale of its DMT Products to physicians, clinics and licensed psychiatrists in the United States, certain countries in the European Union and throughout Canada.

For more information, please contact the Company at:

Entheon Biomedical Corp.
Timothy Ko
Telephone: +1 (604) 562-3932

For media inquiries, please contact Crystal Quast at:

Bullseye Corporate
Crystal Quast
Telephone: +1 (647) 529-6364

Original Source 

Cautionary Note on Forward Looking Information

This news release contains forward‐looking statements and forward‐looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward‐looking statements or information. More particularly and without limitation, this news release contains forward‐looking statements and information relating to the commencement of trading of the Resulting Issuer Shares on the CSE, and other matters. The forward‐looking statements and information are based on certain key expectations and assumptions made by management of the Company. Although management of the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward‐looking statements and information since no assurance can be given that they will prove to be correct. Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of management of the Company relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward‐looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. These include, but are not limited to, the Company’s ability to raise further capital and the Company’s ability to obtain regulatory and exchange approvals. Accordingly, readers should not place undue reliance on the forward‐looking statements and information contained in this news release. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward‐looking statements and information contained in this news release are made as of the date hereof and no undertaking is given to update publicly or revise any forward‐looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement. Neither the CSE nor the Investment Industry Regulatory Organization of Canada accepts responsibility for the adequacy or accuracy of this release.